Evidence map›Paper›PMID 36732627›Full record

Trial reportNature medicine2023

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.

Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang and 15 more

Open access · hybridAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 26 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 26 pooled it
50.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 26 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 2 countries.

Yan Song *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bo Zhang *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0002-6546-8443
Dao Xin *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaoge Kou *Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Zhenbo TanDepartment of Thoracic Surgery, Xingtai People's Hospital, Xingtai, China.
Shu ZhangDepartment of Gastrointestinal Oncology, Shandong First Medical University Cancer Hospital, Shandong Cancer Hospital, Jinan, China.
Meili SunDepartment of Medical Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jin ZhouDepartment of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China.
Min FanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ming ZhangDepartment of Integrated Traditional and Western Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yongxiang SongDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Suyi LiDepartment of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Yuan YuanDepartment of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China.
Wu ZhuangDepartment of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China.
Jingdong ZhangMedical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China.
Li ZhangDepartment of Oncology, Chongqing University Three Gorges Hospital, Chongqing, China.
Hao JiangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Kangsheng GuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Huangyang YeDepartment of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Ying KeShanghai Henlius Biotech, Inc., Shanghai, China.
Jing LiShanghai Henlius Biotech, Inc., Shanghai, China.
Qingyu WangShanghai Henlius Biotech, Inc., Shanghai, China.
Jun ZhuShanghai Henlius Biotech, Inc., Shanghai, China.
Jing HuangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. huangjingwg@163.com.ORCID http://orcid.org/0000-0002-2167-8385
ASTRUM-007 investigators
Chinese Academy of Medical Sciences & Peking Union Medical College · CNZunyi Medical University · CNAnhui Medical University · CNAnhui Provincial Hospital · CNChongqing University · CNFirst Affiliated Hospital of Bengbu Medical College · CNFirst Affiliated Hospital of Xiamen University · CNFirst Affiliated Hospital of Xinxiang Medical University · CNFudan University Shanghai Cancer Center · CNFujian Provincial Cancer Hospital · CNHebei Medical University · CNJinan Central Hospital · CNLiaoning Cancer Hospital & Institute · CNShandong Tumor Hospital · CNShanghai Jiao Tong University · CNSichuan Cancer Hospital · CNXuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L1 combined positive score of ≥1 were randomized (2:1) to receive serplulimab (an anti-PD-1 antibody; 3 mg/kg) or placebo (on day 1), plus cisplatin (50 mg/m

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCisplatinDouble-Blind MethodHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanCisplatin

Identifiers

PMID36732627
PMCPMC9941045
OpenAlexW4318979631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.